Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/993,647
Filing Date	NOVEMBER 27, 2001
First Named Inventor	BERND RIEDL ET AL.
Group Art Unit	1624
Examiner Name	DEEPAK R. RAO
Attorney Docket Number	Bayer-0018-A

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	1		WO 98/22103	PCT	Zeneca Limited GB	05-28-1998		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/993,647
Filing Date	NOVEMBER 27, 2001
First Named Inventor	BERND RIEDL ET AL.
Group Art Unit	1624
Examiner Name	DEEPAK R. RAO
Attorney Docket Number	Bayer-0018-A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	2	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Ghassan K. Abou-Alfa et al., Journal of Clinical Oncology, Vol. 24, No. 26, pp. 4293-4300. September 10, 2003	
	3	Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis, T. Eisen et al., British Journal of Cancer (2006) pp. 581-586	
	4	Randomized Discontinuation Trial of Sorafenib (BAY 43-9006) Lokesh Jain et al., Cancer Biology & Therapy, pp. 1270-1272, October 2006	
	5	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma, Mark J. Ratain et al., Journal of Clinical Oncology, Vol. 24, No. 16, pp. 2505-2510	
	6	Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer, Cesare Gridelli et al., The Oncologist Lung Cancer, pp. 191-200	
	7	First and second generation antisense oligonucleotide inhibitors targeted against human c-raf kinase, Brett P. Monia, Isis Pharmaceuticals Inc., pp. 107-123	
	8	Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha in Patients With Advanced Cancer, J. Nemunaitis et al., Journal of Clinical Oncology, Vol. 17, No. 11, November 1999, pp. 3586-3595	
	9	Phase I Trial of C-raf Antisense Oligonucleotide ISIS 5132 (CGP 69846A) By 21-Day Continuous intravenous Infusion (CIV) in Patients with Advanced Cancer (meeting abstract), American Society of Clinical Oncology, 1998 ASCO Annual Meeting, J. Holmlund et al.	
	10	Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients, Lorigan, P., et al., ASCO 2006 DTIC (abstract final draft) Jan. 11, 2006.	
	11	Phase II Trial of Single-Agent Sorafenib in Patients with Advanced Non-Small-Cell ung Carcinoma, Gatzemeier, U., et al., ASCO 2006 100557 (abstract draft 3) Jan 4, 2006.	
	12	"First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase." Ciba Found Symp. 1997; 209:107-19; discussion 119-23.	
	13	"Phase II Trial of Second Antisense Cancer Drug Begins"; NewsRX Purchased Internet Articles, Antisense Technology (clinical trial).	
	14	"Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-*raf*-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer.", Rudin, Charles M., et al., Clinical Cancer Research, Vol. 7, 1214-1220, May 2001.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+] PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/993,647
Filing Date	NOVEMBER 27, 2001
First Named Inventor	BERND RIEDL ET AL.
Group Art Unit	1624
Examiner Name	DEEPAK R. RAO
Attorney Docket Number	Bayer-0018-A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	15	National Cancer Institute, Clinical Trials (PDQ), www.cancer.gov website, "Phase II Randomized Study of ISIS 5132or ISIS 3521 in Women with Previously Treated Metastatic Breast Cancer; 1998.	
	16	National Cancer Institute, Clinical Trials (PDQ), www.cancer.gov website, "Phase II Randomized Study of ISIS 3521 or ISIS 5132 for Locally Advanced or Metastatic Colorectal Cancer, 1998.	
	17	National Cancer Institute, Clinical Trials (PDQ), www.cancer.gov website, "Phase II Randomized Study of ISIS 3521 or ISIS 5132 in Patients with Hormone Refractory Prostate Cancer, 1998.	
	18	National Cancer Institute, Clinical Trials (PDQ), www.cancer.gov website, "Phase II Randomized Study of ISIS 5132 in Patients with Advanced Pancreatic Cancer (Summary Last Modified 08/1999), 1999	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.